Used in pharmaceutical research as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), this compound plays a key role in the development of treatments for autoimmune diseases and certain B-cell malignancies. Its structure allows for high binding affinity to the BTK enzyme, effectively modulating signaling pathways involved in cell proliferation and survival. Due to its (R)-enantiomeric configuration, it exhibits improved pharmacokinetic properties and reduced off-target effects compared to racemic counterparts. It is primarily investigated in preclinical studies for conditions such as chronic lymphocytic leukemia, rheumatoid arthritis, and other disorders driven by aberrant B-cell activation.